X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
Under the terms of the divestment, Clinigen will divest four medicines, Cardioxane (dexrazoxane), Savene, Totect and Ethyol, all of which help mitigate the side effects patients may experience when treated with other cancer therapies, to CNX Therapeutics.
Lead Product(s): Dexrazoxane
Therapeutic Area: Oncology Product Name: Cardioxane
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CNX Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment August 10, 2023
Details:
Totect® now can be used for reducing the incidence and severity of cardiomyopathy associated with doxorubicin in women with breast cancer who have received a cumulative doxorubicin dose of 300 mg/m² and who will continue to receive doxorubicin therapy.
Lead Product(s): Dexrazoxane
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Totect
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
